

## PHARMACY – 5.01.631

# Pharmacologic Treatment of Clostridioides Difficile

Effective Date: Aug. 1, 2023

Last Revised: Jan. 1, 2024


Replaces: N/A

RELATED MEDICAL POLICIES:

N/A

Select a hyperlink below to be directed to that section.

[POLICY CRITERIA](#) | [DOCUMENTATION REQUIREMENTS](#) | [CODING](#)  
[RELATED INFORMATION](#) | [EVIDENCE REVIEW](#) | [REFERENCES](#) | [APPENDIX](#)  
[HISTORY](#) | [PRIOR AUTHORIZATION REQUIREMENTS](#)

 Clicking this icon returns you to the hyperlinks menu above.

## Introduction

Clostridioides difficile infection (CDI) is a gram-positive, anaerobic, spore-forming bacillus that is responsible for the development of antibiotic-associated diarrhea and colitis. CDI occurs in about 500,000 individuals in the United States every year, with about half of the infections occurring in hospitalized individuals. There are a number of known risk factors for developing CDI. They include antibiotic exposure, gastrointestinal surgery, long stays in healthcare settings (including hospitals and nursing homes), immunocompromising conditions, and age over 65 years. This policy discusses when treatments for CDI may be considered medically necessary.

**Note:** The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

## Policy Coverage Criteria

Drug	Medical Necessity
<b>Rebyota (fecal microbiota, live-jslm) rectal suspension</b>	<p><b>Rebyota (fecal microbiota, live-jslm) may be considered medically necessary when the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• Individual is 18 years of age or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual has had two or more recurrent Clostridioides difficile infection (CDI) episodes</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Positive stool test for toxigenic Clostridioides difficile (C. difficile) within the last 30 days</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Current episode of CDI is controlled defined as less than three loose stools per day for two consecutive days</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Administration will occur within 72 hours following completion of antibacterial treatment for CDI</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Rebyota (fecal microbiota, live-jslm) is limited to a single treatment course</li> </ul>
<b>Vowst (fecal microbiota spores, live-brpk) capsules, for oral administration</b>	<p><b>Vowst (fecal microbiota spores, live-brpk) may be considered medically necessary when the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• Individual is 18 years of age or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual has had two or more recurrent Clostridioides difficile infection (CDI) episodes</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Positive stool test for toxigenic Clostridioides difficile (C. difficile) within the last 30 days</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Current episode of CDI is controlled defined as less than three loose stools per day for two consecutive days</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Administration will occur within 72 hours following completion of antibacterial treatment for CDI</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Vowst (fecal microbiota spores, live-brpk) is limited to a single treatment course</li> </ul>



Drug	Medical Necessity
<b>Zinplava (bezlotoxumab) IV</b>	<p><b>Zinplava (bezlotoxumab) may be considered medically necessary when the following criteria are met:</b></p> <ul style="list-style-type: none"> <li>• Individual is 18 years of age or older</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual has a diagnosis of Clostridioides difficile infection (CDI) confirmed by a positive stool test for toxigenic Clostridioides difficile (C. difficile)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual is at high risk for CDI recurrence due to one of the following: <ul style="list-style-type: none"> <li>○ Individual is 65 years or older</li> </ul> </li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>○ Individual is immunocompromised</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>○ Severe CDI at presentation</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>○ Presence of C. difficile ribotype 027</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Individual is currently receiving standard of care antibacterial therapy for CDI (e.g., fidaxomicin, metronidazole, or vancomycin)</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• Zinplava (bezlotoxumab) is limited to a single treatment course</li> </ul>

Drug	Investigational
<b>Rebyota (fecal microbiota, live-jslm) rectal suspension, Zinplava (bezlotoxumab) IV</b>	<p><b>All other uses of Rebyota (fecal microbiota, live-jslm), Vowst (fecal microbiota spores, live-brpk) and Zinplava (bezlotoxumab) for conditions not outlined in this policy are considered investigational.</b></p>

Length of Approval	
Approval	Criteria
<b>Initial authorization</b>	<p><b>Rebyota (fecal microbiota, live-jslm), Vowst (fecal microbiota spores, live-brpk) and Zinplava (bezlotoxumab) may be approved up to 1 month.</b></p>



Length of Approval	
Approval	Criteria
Re-authorization criteria	<p>Future re-authorization of Rebyota (fecal microbiota, live-jslm) and Vowst (fecal microbiota spores, live-brpk) following the administration of one treatment course is considered investigational.</p> <p>Future re-authorization of Zinplava (bezlotoxumab) following the administration of one dose is considered investigational.</p>

Documentation Requirements
<p>The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:</p> <ul style="list-style-type: none"> <li>Office visit notes that contain the diagnosis, relevant history, physical evaluation, and medication history</li> </ul>

## Coding

Code	Description
<b>HCPCS</b>	
J0565	Injection, bezlotoxumab, 10 mg (Use to report Zinplava)
J1440	Fecal microbiota, live – jslm (Rebyota), 1 ml (new code effective 7/1/2023)
J3590	Unclassified biologics (used to report Vowst)

**Note:** CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

## Related Information



## Benefit Application

Rebyota (fecal microbiota, live-jslm) is managed through the pharmacy and medical benefit. Vowst (fecal microbiota spores, live-brpk) is managed through the pharmacy benefit. Zinplava (bezlotoxumab) is managed through the medical benefit.

## Evidence Review

---

### Clinical Trials

Rebyota was evaluated in the Phase 3 PUNCH CD3 clinical trial (NCT03244644) in individuals with at least one recurrence after a primary episode of CDI or those who have had at least two episodes of severe CDI resulting in hospitalization within the past year. The primary endpoint was absence of *C. difficile* diarrhea without the need for retreatment as assessed by subject interview and physical examination at 8 weeks. Rebyota demonstrated superior efficacy compared with placebo (70.4% and 58.1%, respectively). Safety in the Rebyota arm was comparable to placebo. To evaluate the effectiveness of Rebyota, a Bayesian model was used in which certain results from a placebo-controlled Phase 2 study (PUNCH CD2, NCT02299570) were integrated into the PUNCH CD3 results. All individuals in both trials had a diagnosis of recurrent CDI, although the number of required recurrences differed between trials. The definition of recurrent CDI included diarrhea (passage of three or more loose bowel movements within a 24-hour period for 2 consecutive days) with a positive stool test for *C. difficile* toxin or toxigenic *C. difficile*, or at least two episodes of severe CDI resulting in hospitalization within the last year. All enrolled individuals had completed at least 10 consecutive days of antibiotic therapy. In PUNCH CD3, 87% of individuals had been treated with vancomycin alone. In the integrated efficacy analysis set, the demographic profile and baseline recurrent CDI characteristics of treated adults were similar in the Rebyota and placebo groups.

The efficacy and safety of Vowst was studied in a phase III, randomized, placebo-controlled, multi-center study. The primary efficacy endpoint was to see if there was reduction of CDI recurrence with the Vowst treatment. The study included 182 adult individuals with confirmed diagnosis of recurrent CDI (with a total of  $\geq 3$  episodes of CDI within 12 months) were randomized 1:1 to receive a dose of Vowst ( $n = 89$ ) or placebo ( $n = 93$ ) once daily for 3 consecutive days. One day before starting the assigned treatment regimen, individuals were required to have bowel cleansing using either magnesium citrate or polyethylene glycol electrolyte solution.



The primary efficacy endpoint was CDI recurrence through 8 weeks after completion of treatment. The CDI recurrence was measured through 3 or more unformed stools per day for 2 consecutive days with continued diarrhea until antibacterial treatment was initiated, or a positive *C. difficile* test on a stool sample determined by a toxin assay.

At the end of the week 4, 11.2% in the treatment group and 33.3 % in the placebo group (p-value < 0.001) experienced CDI recurrence. Similarly, at the end of the week 8, 12.4% in the treatment group and 39.8% in the placebo group (p-value < 0.001) experienced CDI recurrence. These statistically significant benefits were maintained through 24 weeks of follow-up.

In the Vowst group, no serious adverse events were observed. Most frequently reported adverse events were GI disorders (abdominal distension, fatigue, constipation, chills and diarrhea).

## References

1. Rebyota (fecal microbiota, live-jslm) prescribing information. Merck Sharp & Dohme Corp. Rahway, NJ. Revised October 2016.
2. Zinplava (bezlotoxumab) prescribing information. Ferring Pharmaceuticals Inc. Saint-Prex, Switzerland. Revised November 2022.
3. Centers for Disease Control and Prevention. FAQs for clinicians about *C. diff*. October 25, 2022. <https://www.cdc.gov/cdiff/clinicians/faq.html> Accessed March 8, 2023.
4. Centers for Disease Control and Prevention. Nearly half a million Americans suffered from *Clostridium difficile* infections in a single year. March 22, 2017. <https://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html> Accessed March 8, 2023.
5. Dubberke ER, et al. Results from a randomized, placebo-controlled clinical trial of a RBX2660- a microbiota-based drug for the prevention of recurrent *Clostridium difficile* Infection. *Clin Infect Dis*. 2018;67(8):1198–1204. doi:10.1093/cid/ciy259
6. Gough E, et al. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis*. 2011;53(10):994– 1002. doi:10.1093/cid/cir632
7. Guh AY, et al. Trends in U.S. burden of *Clostridioides difficile* infection and outcomes. *New Engl J Med*. 2020;382:1320–1330. doi:10.1056/NEJMoa1910215
8. Gupta S, et al. Fecal microbiota transplantation: in perspective. *Therap Adv Gastroenterol*. 2016;9(2):229–239. doi:10.1177/1756283X15607414
9. Khanna S, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent *Clostridioides difficile* infection [published correction appears in *Drugs*. 2022]. *Drugs*. 2022;82(15):1527–1538. doi:10.1007/s40265-022-01797-x
10. Kwak S, et al. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. *Microbiome*. 2020;8(1):125. doi:10.1186/s40168-020-00907-9
11. Langdon A, et al. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent *Clostridioides difficile* infection from the open-label PUNCH CD study. *Genome Med*. 2021;13(1):28. doi:10.1186/s13073-021-00843-9



12. Moayyedi P, et al. Canadian Association of Gastroenterology position statement: fecal microbiota transplant therapy. *Can J Gastroenterol Hepatol*. 2014;28(2):66–68. doi:10.1155/2014/346590
13. Orenstein R, et al. Durable reduction of *Clostridioides difficile* infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. *BMC Infect Dis*. 2022;22(1):245. doi:10.1186/s12879-022-07256-y
14. Orenstein R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent *Clostridium difficile* infection: Results of the PUNCH CD Study. *Clin Infect Dis*. 2016;62(5):596–602. doi:10.1093/cid/civ938
15. Rohlke F, Stollman N. Fecal microbiota transplantation in relapsing *Clostridium difficile* infection. *Therap Adv Gastroenterol*. 2012;5(6):403–420. doi:10.1177/1756283X12453637
16. Song JH, et al. Recurrent *Clostridium difficile* infection: risk factors, treatment and prevention. *Gut Liver*. 2019;13(1):16–24. doi:10.5009/gnl18071
17. Suzuki R, et al. Contact urticaria syndrome and protein contact dermatitis caused by glycerin enema. *JAAD Case Rep*. 2016;2(2):108–110. doi: 10.1016/j.jdc.2015.12.011
18. U.S. Food and Drug Administration. FDA approves first fecal microbiota product. November 30, 2022. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-fecal-microbiota-product> Accessed March 8, 2023.
19. U.S. Food and Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. Updated December 4, 2020. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse> Accessed March 8, 2023.
20. U.S. Food and Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to monkeypox virus. August 22, 2022. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections-0> Accessed March 8, 2023.
21. U.S. Food and Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19. March 23, 2020. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections> Accessed March 8, 2023.
22. U.S. Food and Drug Administration. Update to March 12, 2020 safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse events likely due to transmission of pathogenic organisms. March 13, 2020. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/update-march-12-2020-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious> Accessed March 8, 2023.
23. van Nood E, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med*. 2013;368(5):407–415. doi:10.1056/NEJMoa1205037
24. Vowst™ (fecal microbiota spores, live-brpk), Prescribing Information. Aimmune Therapeutics, Inc. Brisbane, CA. Revised April 2023.
25. Lisa M, et al. ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent *Clostridium Difficile* Infection (ECOSPORIII). Available at: ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent *Clostridium Difficile* Infection - Full Text View - ClinicalTrials.gov. Accessed on June 23, 2023.
26. Elaine W, et al. ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent *Clostridioides Difficile* Infection. Available at: ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent *Clostridioides Difficile* Infection - Full Text View - ClinicalTrials.gov. Accessed on June 23, 2023.



## History

Date	Comments
04/01/23	New policy, approved March 14, 2023, effective for dates of service on or after July 6, 2023. Added Rebyota (fecal microbiota, live-jslm) and Zinplava (bezlotoxumab) coverage criteria. Added HCPC code Zinplava and code J3590 for Rebyota.
07/01/23	Coding update. Added new HCPCS code J1440.
08/01/23	Interim Review, approved July 11, 2023. Added Vowst (fecal microbiota spores, live-brbk) coverage criteria. Added Vowst to HCPCS code J1440.
01/01/24	Coding update and coding correction. Vowst removed from HCPCS code J1440 and added to HCPCS code J3590.

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2024 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.





## Discrimination is Against the Law

Premera Blue Cross (Premera) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). Premera provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator — Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-4535, Fax: 425-918-5592, TTY: 711, Email [AppealsDepartmentInquiries@Premera.com](mailto:AppealsDepartmentInquiries@Premera.com). You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

**Washington residents:** You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at <https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status>, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at <https://fortress.wa.gov/oic/online-services/cc/pub/complaintinformation.aspx>.

**Alaska residents:** Contact the Alaska Division of Insurance via email at [insurance@alaska.gov](mailto:insurance@alaska.gov), or by phone at 907-269-7900 or 1-800-INSURAK (in-state, outside Anchorage).

## Language Assistance

**ATENCIÓN:** si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-722-1471 (TTY: 711).

**PAUNAWA:** Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-722-1471 (TTY: 711).

**注意:** 如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-722-1471 (TTY: 711)。

**CHÚ Ý:** Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-722-1471 (TTY: 711).

**주의:** 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-722-1471 (TTY: 711) 번으로 전화해 주십시오.

**ВНИМАНИЕ:** Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-722-1471 (телетайп: 711).

**LUS CEEV:** Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 800-722-1471 (TTY: 711).

**MO LOU SILAFIA:** Afai e te tautala Gagana fa'a Sāmoa, o loo iai auunaga fesoasoan, e fai fua e leai se totagi, mo oe, Telefoni mai: 800-722-1471 (TTY: 711).

**ໂປດອຸລາ:** ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ຄມມນມີພ້ອມໃຫ້ທ່ານ. ໂທ 800-722-1471 (TTY: 711).

**注意事項:** 日本語を話される場合、無料の言語支援をご利用いただけます。800-722-1471 (TTY:711) まで、お電話にてご連絡ください。

**PAKDAAR:** Nu saritaem ti Ilocano, ti serbisyo para ti baddang ti lengguahe nga awanan bayadna, ket sidadaan para kenyan. Awagan ti 800-722-1471 (TTY: 711).

**УВАГА!** Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки. Телефонуйте за номером 800-722-1471 (телетайп: 711).

**ប្រយ័ត្ន:** បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតលុយ គឺអាចមានសំរាប់អ្នក។ ចូរ ទូរស័ព្ទ 800-722-1471 (TTY: 711)។

**ማስታወሻ:** የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም አርዳታ ድርጅቶች: በነጻ ሊያግኙዎት ተዘጋጅተዋል: ወደ ሚከተለው ቁጥር ይደውሉ 800-722-1471 (መስማት ለተሳናቸው: 711).

**XIYYEEFFANNAA:** Afaan dubbattu Oroomiffa, tajaajjila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-722-1471 (TTY: 711).

**ملحوظة:** إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-722-1471 (رقم هاتف الصم والبكم: 711).

**ਧਿਆਨ ਦਿਓ:** ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-722-1471 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

**ထိစား:** ถ้าคุณพูดภาษาไทยคุณสามารถใช้บริการช่วยเหลือทางภาษาได้ฟรี โทร 800-722-1471 (TTY: 711).

**ACHTUNG:** Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-722-1471 (TTY: 711).

**UWAGA:** Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-722-1471 (TTY: 711).

**ATANSYON:** Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 800-722-1471 (TTY: 711).

**ATTENTION:** Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-722-1471 (ATS: 711).

**ATENÇÃO:** Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-722-1471 (TTY: 711).

**ATTENZIONE:** In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-722-1471 (TTY: 711).

**توجہ:** اگر بہ زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-722-1471 (TTY: 711) تماس بگیرید.